BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31902040)

  • 21. IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI.
    Lin Y; Xing Z; She D; Yang X; Zheng Y; Xiao Z; Wang X; Cao D
    Neuroradiology; 2017 Jun; 59(6):555-562. PubMed ID: 28474187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential implementation of DSC-MR perfusion and dynamic [
    Steidl E; Langen KJ; Hmeidan SA; Polomac N; Filss CP; Galldiks N; Lohmann P; Keil F; Filipski K; Mottaghy FM; Shah NJ; Steinbach JP; Hattingen E; Maurer GD
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1956-1965. PubMed ID: 33241456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Which is the best advanced MR imaging protocol for predicting recurrent metastatic brain tumor following gamma-knife radiosurgery: focused on perfusion method.
    Koh MJ; Kim HS; Choi CG; Kim SJ
    Neuroradiology; 2015 Apr; 57(4):367-76. PubMed ID: 25592446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
    Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
    Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
    Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
    Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic role of apparent diffusion coefficient combined with intratumoral susceptibility signals in differentiating high-grade gliomas from brain metastases.
    Bozdağ M; Er A; Çinkooğlu A; Ekmekçi S
    Neuroradiol J; 2021 Jun; 34(3):169-179. PubMed ID: 33307971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic value of apparent diffusion coefficient in differentiating between high-grade gliomas and brain metastases.
    Caravan I; Ciortea CA; Contis A; Lebovici A
    Acta Radiol; 2018 May; 59(5):599-605. PubMed ID: 28835111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-invasive prediction of p53 and Ki-67 labelling indices and O-6-methylguanine-DNA methyltransferase promoter methylation status in adult patients with isocitrate dehydrogenase wild-type glioblastomas using diffusion-weighted imaging and dynamic susceptibility contrast-enhanced perfusion-weighted imaging combined with conventional MRI.
    Xing Z; Huang W; Su Y; Yang X; Zhou X; Cao D
    Clin Radiol; 2022 Aug; 77(8):e576-e584. PubMed ID: 35469666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced (DCE) vs. dynamic susceptibility contrast (DSC) MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas.
    Zakhari N; Taccone MS; Torres CH; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Cron GO; Thornhill RE; McInnes MDF; Nguyen TB
    J Magn Reson Imaging; 2019 Aug; 50(2):573-582. PubMed ID: 30614146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiparametric MRI in differentiating solitary brain metastasis from high-grade glioma: diagnostic value of the combined use of diffusion-weighted imaging, dynamic susceptibility contrast imaging, and magnetic resonance spectroscopy parameters.
    Aslan K; Gunbey HP; Tomak L; Incesu L
    Neurol Neurochir Pol; 2019; 53(3):227-237. PubMed ID: 31180131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects.
    Fink JR; Carr RB; Matsusue E; Iyer RS; Rockhill JK; Haynor DR; Maravilla KR
    J Magn Reson Imaging; 2012 Jan; 35(1):56-63. PubMed ID: 22002882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiation Between True Tumor Progression of Glioblastoma and Pseudoprogression Using Diffusion-Weighted Imaging and Perfusion-Weighted Imaging: Systematic Review and Meta-analysis.
    Tsakiris C; Siempis T; Alexiou GA; Zikou A; Sioka C; Voulgaris S; Argyropoulou MI
    World Neurosurg; 2020 Dec; 144():e100-e109. PubMed ID: 32777397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease.
    Seeger A; Braun C; Skardelly M; Paulsen F; Schittenhelm J; Ernemann U; Bisdas S
    Acad Radiol; 2013 Dec; 20(12):1557-65. PubMed ID: 24200483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three-dimensional arterial spin labeling imaging and dynamic susceptibility contrast perfusion-weighted imaging value in diagnosing glioma grade prior to surgery.
    Ma H; Wang Z; Xu K; Shao Z; Yang C; Xu P; Liu X; Hu C; Lu X; Rong Y
    Exp Ther Med; 2017 Jun; 13(6):2691-2698. PubMed ID: 28587332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging.
    Park MJ; Kim HS; Jahng GH; Ryu CW; Park SM; Kim SY
    AJNR Am J Neuroradiol; 2009 Aug; 30(7):1402-8. PubMed ID: 19369602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diffusion and perfusion MR patterns of central nervous system lymphomas.
    Neska-Matuszewska M; Zimny A; Bladowska J; Sąsiadek M
    Adv Clin Exp Med; 2018 Aug; 27(8):1099-1108. PubMed ID: 29975467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region.
    Xing Z; Zhang H; She D; Lin Y; Zhou X; Zeng Z; Cao D
    Acta Radiol; 2019 Dec; 60(12):1663-1672. PubMed ID: 31084193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differentiation of high-grade from low-grade diffuse gliomas using diffusion-weighted imaging: a comparative study of mono-, bi-, and stretched-exponential diffusion models.
    Kusunoki M; Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Hata N; Mizoguchi M; Iihara K; Suzuki SO; Iwaki T; Akamine Y; Hiwatashi A
    Neuroradiology; 2020 Jul; 62(7):815-823. PubMed ID: 32424712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-invasive assessment of heterogeneity of gliomas using diffusion and perfusion MRI: correlation with spatially co-registered PET.
    Zhang Y; Lin Y; Xing Z; Yao S; Cao D; Miao WB
    Acta Radiol; 2022 May; 63(5):664-671. PubMed ID: 33858207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.